NEW YORK, May 28, 2025 /PRNewswire/ -- Kyndryl (NYSE: KD), a leading provider of mission-critical enterprise technology services, today announced that it is working with the Virginia Department of Motor Vehicles (DMV) to modernize the customer experience. The initiative aims to speed up and improve the processing of over 200,000 transactions daily.The Virginia DMV has engaged Kyndryl to replace its Citizen Services Solution (CSS) with a cloud-native architecture to power its vehicle, driver and business app ...

Core Insights - Spectral Medical Inc. has completed enrollment for its Tigris trial, a Phase III clinical trial evaluating PMX for endotoxic septic shock, with topline results expected in August 2025 [1][2][3] - The company has entered into a promissory note agreement with Vantive for up to US$10 million to support PMX commercialization [1][9] Clinical Development - The Tigris trial has enrolled a total of 157 patients, with 151 evaluable patients and 100 treated with PMX [6] - The data lock for the trial is expected to be completed in approximately 90 days, with topline results anticipated two weeks post-data lock [6] - The company is on track to submit clinical results to the FDA by the end of October 2025 [6] Financial Performance - Revenue for Q1 2025 was $572,000, a decrease of 14% from $668,000 in Q1 2024 [10] - Operating expenses increased significantly to $13,174,000, up 173% from $4,825,000 in the prior year, primarily due to non-cash fair value adjustments [11] - The company reported a loss of $12,605,000 for Q1 2025, compared to a loss of $4,160,000 in Q1 2024 [13] Balance Sheet and Financing - As of March 31, 2025, the company had cash of $1,670,000, down from $2,988,000 at the end of 2024 [14] - The promissory note with Vantive includes a four-year maturity and a payment-in-kind interest rate of 9% [15] Commercialization Activities - The company is collaborating with Vantive on post-approval marketing plans for PMX commercialization [15] - Vantive intends to submit a 510(k) application for its PrisMax System, which is expected to be the primary device used for PMX treatments upon commercial launch [15] Regulatory and Clinical Study Insights - The EDEN study, completed in Q4 2023, showed that patients with endotoxic septic shock had a significantly higher mortality rate of 60% compared to 14.1% for other septic shock patients [6] - The results from the EDEN study will inform discussions with the FDA regarding PMX labeling and the addressable population in the U.S. [6]

Financial Data and Key Metrics Changes - IMAX Corporation achieved nearly $300 million in global box office for Q1 2025, marking its best first quarter ever [10] - Revenue for Q1 was $87 million, up 10% year-over-year, with adjusted EBITDA margin at 42.7%, an increase of over 200 basis points year-over-year [34][40] - Adjusted EBITDA for the quarter was $37 million, reflecting a 15% increase year-over-year [39] Business Line Data and Key Metrics Changes - Content Solutions revenues grew to $34 million, with a gross margin of $24 million, up 7% year-over-year [35] - Technology products and services revenues increased to $51 million, up 17% year-over-year, with a gross margin of $29 million, up 23% [36] - The company installed 21 systems worldwide in Q1, its second-best first quarter for installations, with a total backlog of 516 systems, up 17% year-over-year [29][38] Market Data and Key Metrics Changes - IMAX Corporation's global market share reached 3.5% in Q1, with a record 5.4% in China [35] - Local language films accounted for 68% of IMAX's box office in Q1 2025, a significant increase from 21% in 2023 [20] Company Strategy and Development Direction - The company is focusing on expanding its local language film strategy, with significant growth expected in markets like China, Japan, and India [15][18] - IMAX Corporation is leveraging its relationships with studios and filmmakers to enhance its content offerings and maintain a diverse programming slate [14][46] - The company is optimistic about its future slate, with a strong pipeline of films scheduled through the end of the decade [32][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that the recent reduction in Hollywood imports in China will not materially impact IMAX's business, as it primarily affects smaller budget films [12][55] - The company anticipates continued growth in box office performance, driven by a strong film slate and increasing consumer interest [45][46] - Management highlighted the resilience of the IMAX brand and its ability to thrive in various economic cycles [32] Other Important Information - The company reported cash flow from operations of $7 million in Q1, an improvement of $18 million year-over-year [42] - IMAX Corporation's capital position remains strong, with $97 million in cash and over $400 million in available liquidity [44] Q&A Session Summary Question: Impact of Hollywood film imports reduction in China - Management indicated that there is increased interest in films and no reduction in activity in the Chinese market, with a positive narrative surrounding IMAX [51][55] Question: Factors affecting the percentage of films shot with IMAX cameras - Management stated that the primary limiting factor is the availability of slots for films rather than the number of cameras [58] Question: Strength of IMAX's performance in China - Management noted that the strong performance was uniform across all markets, driven by effective marketing strategies and a special film release [64][66] Question: Concerns about the health of the consumer - Management expressed confidence that IMAX remains an affordable luxury, with box office performance resilient even during economic downturns [104] Question: Brand perception of IMAX in China - Management clarified that IMAX is viewed as a local prestige brand in China, with strong consumer appreciation [135]